Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cevostamab and Elranatamab in Relapsed or Refractory Multiple Myeloma
NCT05927571Phase 1Recruiting
- Sponsor
- Genentech
- Start
- Aug 2023
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of cevostamab and elranatamab in multiple myeloma (MM) (3 cohorts), sponsored by Genentech. Primary endpoints: Number of Participants With Adverse Events at 36 months and Recommended Phase II Regimen at 36 months. Started Aug 2023; status: recruiting.
02
Drugs
cevostamabelranatamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT05927571.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05927571.